Vicore Pharma Holding AB (publ)

OM:VICO Stock Report

Market Cap: SEK 1.8b

Vicore Pharma Holding Valuation

Is VICO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VICO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VICO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VICO's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VICO?

Key metric: As VICO barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for VICO. This is calculated by dividing VICO's market cap by their current book value.
What is VICO's PB Ratio?
PB Ratio1.8x
BookSEK 1.02b
Market CapSEK 1.81b

Price to Book Ratio vs Peers

How does VICO's PB Ratio compare to its peers?

The above table shows the PB ratio for VICO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average6.4x
SANION Saniona
4.7xn/aSEK 1.1b
DVYSR Devyser Diagnostics
5.2x107.0%SEK 1.7b
EGTX Egetis Therapeutics
3x69.0%SEK 1.3b
CRNO B Cereno Scientific
12.7xn/aSEK 2.4b
VICO Vicore Pharma Holding
1.8x36.5%SEK 1.8b

Price-To-Book vs Peers: VICO is good value based on its Price-To-Book Ratio (1.8x) compared to the peer average (6.4x).

Price to Book Ratio vs Industry

How does VICO's PB Ratio compare vs other companies in the SE Biotechs Industry?

7 CompaniesPrice / BookEstimated GrowthMarket Cap
IMMU Mendus
0.5x12.8%US$31.14m
SPERM Spermosens
0.4xn/aUS$1.24m
PROGEN Prostatype Genomics
0.3xn/aUS$1.14m
APTA Aptahem
0.1xn/aUS$1.00m
VICO 1.8xIndustry Avg. 2.4xNo. of Companies11PB0246810+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: VICO is good value based on its Price-To-Book Ratio (1.8x) compared to the Swedish Biotechs industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is VICO's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VICO PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate VICO's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VICO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 7.70
SEK 31.52
+309.4%
27.4%SEK 40.00SEK 19.00n/a6
May ’26SEK 8.31
SEK 31.52
+279.3%
27.4%SEK 40.00SEK 19.00n/a6
Apr ’26SEK 7.19
SEK 34.03
+373.2%
21.1%SEK 40.00SEK 20.00n/a5
Mar ’26SEK 7.92
SEK 34.03
+329.6%
21.1%SEK 40.00SEK 20.00n/a5
Feb ’26SEK 9.09
SEK 34.03
+274.3%
21.1%SEK 40.00SEK 20.00n/a5
Jan ’26SEK 8.45
SEK 34.03
+302.7%
21.1%SEK 40.00SEK 20.00n/a5
Dec ’25SEK 7.84
SEK 34.03
+334.0%
21.1%SEK 40.00SEK 20.00n/a5
Nov ’25SEK 8.00
SEK 35.99
+349.9%
8.1%SEK 40.00SEK 32.00n/a4
Oct ’25SEK 7.81
SEK 36.32
+365.1%
9.1%SEK 40.00SEK 32.00n/a3
Sep ’25SEK 16.46
SEK 50.50
+206.8%
30.1%SEK 70.00SEK 32.00n/a4
Aug ’25SEK 17.90
SEK 61.50
+243.6%
31.0%SEK 84.00SEK 32.00n/a4
Jul ’25SEK 20.05
SEK 61.50
+206.7%
31.0%SEK 84.00SEK 32.00n/a4
Jun ’25SEK 22.00
SEK 61.50
+179.5%
31.0%SEK 84.00SEK 32.00n/a4
May ’25SEK 18.06
SEK 61.50
+240.5%
31.0%SEK 84.00SEK 32.00SEK 8.314
Apr ’25SEK 14.68
SEK 61.50
+318.9%
31.0%SEK 84.00SEK 32.00SEK 7.194
Mar ’25SEK 14.38
SEK 68.60
+377.1%
32.3%SEK 97.00SEK 32.00SEK 7.925
Feb ’25SEK 13.30
SEK 70.75
+432.0%
34.4%SEK 97.00SEK 32.00SEK 9.094
Jan ’25SEK 14.18
SEK 70.75
+398.9%
34.4%SEK 97.00SEK 32.00SEK 8.454
Dec ’24SEK 15.38
SEK 70.75
+360.0%
34.4%SEK 97.00SEK 32.00SEK 7.844
Nov ’24SEK 12.72
SEK 70.75
+456.2%
34.4%SEK 97.00SEK 32.00SEK 8.004
Oct ’24SEK 15.30
SEK 70.75
+362.4%
34.4%SEK 97.00SEK 32.00SEK 7.814
Sep ’24SEK 15.58
SEK 70.75
+354.1%
34.4%SEK 97.00SEK 32.00SEK 16.464
Aug ’24SEK 18.28
SEK 70.75
+287.0%
34.4%SEK 97.00SEK 32.00SEK 17.904
Jul ’24SEK 17.12
SEK 70.50
+311.8%
35.1%SEK 97.00SEK 31.00SEK 20.054
Jun ’24SEK 17.66
SEK 72.00
+307.7%
31.0%SEK 97.00SEK 31.00SEK 22.005
May ’24SEK 19.16
SEK 70.00
+265.3%
29.8%SEK 97.00SEK 31.00SEK 18.066
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
SEK 31.52
Fair Value
75.6% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/07 08:33
End of Day Share Price 2025/05/07 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vicore Pharma Holding AB (publ) is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hanseung YooBryan Garnier & Co
Oscar Haffen LammBryan Garnier & Co
Gonzalo Artiach CastanonDanske Bank